ライフサイエンスコーパス: plasmacytoma

1 ng smouldering multiple myeloma and solitary plasmacytoma.

2 ) and CD45-reconstituted (CD45+) J558L mu m3 plasmacytoma.

3 glycoprotein), was recently isolated from a plasmacytoma.

4 ies to subsets of human multiple myeloma and plasmacytoma.

5 in human endemic Burkitt lymphoma and mouse plasmacytoma.

6 igh-grade angiogenesis was present in 64% of plasmacytomas.

7 sing an Emicro-v-abl oncogene solely develop plasmacytomas.

8 d and significantly suppressed the growth of plasmacytomas.

9 d the function of this enhancer in mammalian plasmacytomas.

10 ecursor clones into Igh alpha/c-myc-positive plasmacytomas.

11 o reflect the general genomic instability of plasmacytomas.

12 l translocations in t(12;15)-positive BALB/c plasmacytomas.

13 ry cytogenetic aberrations in primary BALB/c plasmacytomas.

14 ulated into BALB/c mice to produce growth of plasmacytomas.

15 nal A-type particle long terminal repeats in plasmacytomas.

16 , 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.

17 ging System stage III, high tumor burden, or plasmacytomas.

18 pathway to confer IL6 independence on murine plasmacytomas.

19 s, and macrophages not seen with plasmacytic plasmacytomas.

20 features of transgenic and pristane-induced plasmacytomas.

21 cation that deregulates Myc in certain mouse plasmacytomas.

22 vation of Myc in the great majority of mouse plasmacytomas.

23 ve mutant or a structural homolog, protected plasmacytomas against IL6 withdrawal-induced apoptosis a

24 s affecting c-myc occur in almost all murine plasmacytoma and human Burkitt's lymphoma tumors and are

25 ned if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely

26 Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progressi

27 Specific resistance was generated both to a plasmacytoma and lymphoma.

28 IL-6 in both IL-6-dependent and -independent plasmacytomas and hybridomas were compared.

29 significantly accelerated the development of plasmacytomas and increased their incidence.

30 adioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma has undergone only li

31 dominantly develop late stage B cell tumors (plasmacytomas) and less frequently develop earlier B-lin

32 tterns held up in murine xenograft models of plasmacytoma, and disseminated bone marrow predominant d

33 Extramedullary plasmacytomas are highly radiosensitive and radiotherapy

34 Murine plasmacytomas are tumors of Ig-secreting plasma cells th

35 tin superfamily of adhesion molecules, Pang (plasmacytoma-associated neuronal glycoprotein), was rece

36 ar; seven of these 14 displayed extraosseous plasmacytomas at diagnosis and/or relapse.

37 y and light chain V gene usage in these same plasmacytomas at the DNA and RNA level.

38 In plasmacytoma-bearing mice (n = 7), mutant frequencies in

39 r studies reveal: (a) antibodies secreted by plasmacytomas bind to different antigens in a manner sim

40 We studied angiogenesis in plasmacytoma biopsy samples and bone marrow biopsies fro

41 lasms (PCNs, comprising multiple myeloma and plasmacytoma), but little is known about risk factors in

42 raise suspicion about associated lymphoma or plasmacytoma, but negative PET results do not exclude th

43 was observed in one of the IL-6-independent plasmacytomas, but not in others, making an autocrine me

44 kground of C increased the incidence of GALT plasmacytomas by a factor of 2.5 in first-generation bac

45 st cell-derived Ang-1 promotes the growth of plasmacytomas by stimulating neovascularization and prov

46 eristic of Burkitt lymphomas (BL) and murine plasmacytomas, c-myc genes become juxtaposed to immunogl

47 lear factor-IL-6beta-Ig/EBP-1 heterodimer in plasmacytoma cell extracts.

48 In this study we used IL-6-dependent plasmacytoma cell line B9 and CD4 T cells from IL-27Ralp

49 activated endogenous mb-1 transcription in a plasmacytoma cell line, but could not when the promoter

50 ning the B29 octamer motif is expressed in a plasmacytoma cell line, while the wild-type mb-1 promote

51 termined with a bioassay using the murine B9 plasmacytoma cell line.

52 proliferation of the IL-6-dependent B9 mouse plasmacytoma cell line.

53 unterpart in inducing growth arrest of mouse plasmacytoma cell lines and preventing ras-induced trans

54 cells accelerate tumor growth by established plasmacytoma cell lines and that neutralization of Ang-1

55 but not Ang-2 and that 2 established murine plasmacytoma cell lines express high levels of VEGF-A bu

56 f cell death in IL-6-starved T1165 and T1198 plasmacytoma cell lines is apoptosis, and that it can be

57 spond to this approach, we examined 3 murine plasmacytoma cell lines, 2 (MPC-11 and S107) expressing

58 For all 3 plasmacytoma cell lines, coinjection with CL7.1/mCD40L s

59 inhibitor of FRAP, did not inhibit growth of plasmacytoma cell lines.

60 d expression of linked c-myc genes in BL and plasmacytoma cell lines.

61 embrane-encoding Ighg2b transcripts in MPC11 plasmacytoma cell lines.

62 tion that p28/CLF, unlike IL-27, sustains B9 plasmacytoma cell proliferation prompted us to investiga

63 e is evolutionarily conserved and exhibits a plasmacytoma cell-specific DNase I-hypersensitive site i

64 We also identified a plasmacytoma cell-specific HS in the far downstream regi

65 EBF1 and RUNX1 in terminally differentiated plasmacytoma cells activated multiple early B cell-speci

66 ve NF-kappaB activation, similarly protected plasmacytoma cells against IL6 withdrawal-induced apopto

67 gize with E47 inhibited enhancer activity in plasmacytoma cells and could not activate transcription

68 t XBP-1(S) binds to the promoter of ERdj3 in plasmacytoma cells and in LPS-stimulated primary splenic

69 romoter activity was up-regulated by BSAP in plasmacytoma cells and T cells in a dose-dependent manne

70 survival factors for malignant lymphoma and plasmacytoma cells derived from transgenic Emu-Myc mice

71 Plasmacytoma cells expressing MIP-1 alpha generate a cyt

72 CD40L were injected together with apoptotic plasmacytoma cells from these tumors.

73 e eradicated s.c. implants of 10(6) J558L HI plasmacytoma cells in 6 of 13 mice.

74 s Ang-1, and recombinant Ang-1 together with plasmacytoma cells promotes extracellular matrix neovasc

75 d, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DC

76 tor expression in both fibroblasts and mouse plasmacytoma cells, and Mzf1 knockdown increased Mtor ex

77 ression of a number of genes in AID-silenced plasmacytoma cells, and upregulation of CD200 was shown

78 dogenous early B-cell-specific mb-1 genes in plasmacytoma cells, but only when the promoter is hypome

79 Lysine 170 was acetylated in pre-B cells and plasmacytoma cells, but TSA treatment did not stimulate

80 istent inactivation of TGF-beta receptors in plasmacytoma cells, demonstrating for the first time tha

81 However in S194 plasmacytoma cells, mitogen-activated protein kinase kin

82 h received chambers containing untransfected plasmacytoma cells, secreted primarily IL-2 and IL-4, wi

83 matrix components shows that mast cells and plasmacytoma cells, together, promote marked neovascular

84 his study, we have fused DCs with mouse 4TOO plasmacytoma cells.

85 nal APCs rather than from CD40 activation of plasmacytoma cells.

86 kappaE3'-enhancer activity in both pre-B and plasmacytoma cells.

87 ibution and is expressed on T cells and some plasmacytoma cells.

88 ter variants and transfected them into mouse plasmacytoma cells.

89 ergistic activation of mb-1 transcription in plasmacytoma cells.

90 h VEGF-A reduces significantly the growth of plasmacytomas containing mast cells.

91 nd 3' RR elements in MPC11, which like other plasmacytomas contains a reciprocal translocation betwee

92 ted that the iMyc(Emu) transgene accelerates plasmacytoma development by collaborating with tumor sus

93 hromosomal aberrations to the progression of plasmacytoma development has been largely ignored.

94 ns (oil granulomata) during pristane-induced plasmacytoma development in susceptible BALB/cAn mice.

95 uencies, in strains genetically resistant to plasmacytoma development, such as DBA/2.

96 at small interfering RNA silencing of AID in plasmacytoma dramatically increased its susceptibility t

97 Extramedullary plasmacytoma (EMP) is a plasma cell neoplasm of soft tis

98 control and survival rates of extramedullary plasmacytoma (EMP) with respect to various treatment app

99 lasmacytoma (SBP; n = 35) and extramedullary plasmacytoma (EMP; n = 29) through multiparameter flow c

100 ll neoplasms resembling human extramedullary plasmacytoma (EP) as well as follicular and diffuse larg

101 y reduces kiss1 and serotonin-related genes (plasmacytoma expressed transcript 1 and solute carrier f

102 at the light chain level with at least three plasmacytomas expressing both kappa and lambda light cha

103 Plasmablastic plasmacytomas from NFS.V(+) and SJL-beta2M(-/-) mice did

104 gene expression profiles of newly identified plasmacytomas from NFS.V(+) congenic mice with plasmacyt

105 emic Burkitt lymphoma-like translocations in plasmacytomas from uracil N-glycosylase and activation-i

106 The majority of BALB/c mouse plasmacytomas harbor a balanced T(12;15) chromosomal tra

107 f monoclonal immunoglobulin (Ig) produced by plasmacytomas have found no universally common binding p

108 Our results for plasmacytomas highlight the significance of antiapoptoti

109 K in AF-10 MM cells and IL-6-dependent MH.60 plasmacytoma/hybridoma cells.

110 ified, is a tumor rejection antigen for J558 plasmacytoma in mice with an unperturbed T-cell repertoi

111 e, these translocations are able to generate plasmacytomas in each transgenic line.

112 egulates Mtor expression in pristane-induced plasmacytomas in mice.

113 s found in Burkitt's lymphomas in humans and plasmacytomas in mice.

114 in humans and with pristane- and IL6-induced plasmacytomas in mice.

115 ping (SKY) to evaluate 10 established BALB/c plasmacytomas in which the T(12;15) had been previously

116 ded by the Pctm locus, in which mouse B-cell plasmacytomas induced by pristane are associated with he

117 Plasmacytomas induced in BALB/c mice by pristane consist

118 Here, we report that a nonmetastatic B7+ plasmacytoma induces strong effector CTL response.

119 he genetic susceptibility of BALB/c mice for plasmacytoma induction and that p16(INK4a) is a strong c

120 Susceptibility to plasmacytoma induction by intraperitoneal pristane in mi

121 Mice that are resistant to plasmacytoma induction can also harbor recombination-pos

122 lambdaLIZ N5 mice in the terminal stage of a plasmacytoma induction experiment, 213-280 days after th

123 ing, anionic Stealth liposomes can eradicate plasmacytomas infiltrated by eosinophils in mice.

124 and Myc in Burkitt's lymphoma and in murine plasmacytoma is a classic example.

125 Solitary plasmacytoma is a localized plasma cell malignancy that

126 ptibility of BALB/c mice to pristane-induced plasmacytomas is a complex genetic trait involving multi

127 step in the malignant progression of murine plasmacytomas is the transition from dependence on IL-6

128 tumor immunity, we generated IL-35-producing plasmacytoma J558 and B16 melanoma cells and observed th

129 ited into B7-1-transfected class II-negative plasmacytoma J558, and the virus-infected central nervou

130 /-) mice were challenged with P1A-expressing plasmacytoma J558.

131 uitment of CD8 T cells into B7-1-transfected plasmacytoma J558.

132 ne mustard) to mice bearing a large MOPC-315 plasmacytoma led to a rapid up-regulation of B7-1 (CD80)

133 World Health Organization classification) to plasmacytoma like.

134 nds to the OBF-1/BOB-1/OCA-B promoter in the plasmacytoma line and in primary B cells not only during

135 This repression can occur in plasmacytoma lines or in a non-B-cell line in which the

136 RNA was used to decrease XBP-1 expression in plasmacytoma lines, ERdj3 transcripts were concomitantly

137 nic acid, a very-long-chain FFA, in a murine plasmacytoma model displayed a reduction in tumor burden

138 odels: human MM injected subcutaneously (the plasmacytoma model) and luciferase-expressing human MM i

139 r, despite some evidence obtained from mouse plasmacytoma models, it is still unclear whether Id-spec

140 es significant antitumor activity in a human plasmacytoma mouse model, associated with down-regulatio

141 Using a plasmacytoma mouse model, we show that AID(+/-) mice hav

142 nesis, and prolongs host survival in a human plasmacytoma mouse model.

143 owth and prolonged survival in a human MM.1S plasmacytoma murine xenograft model.

144 lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tis

145 In plasmacytoma-negative mice (n = 11), mutant frequencies

146 location in all of these tumors and in three plasmacytomas newly identified secondary cytogenetic cha

147 e plasma cell stage, we fused 70Z/3 with the plasmacytoma NSO.

148 rrow disease (OMD) in patients with solitary plasmacytoma of bone and assess its value in predicting

149 1, 9732, and 9734 were assigned for solitary plasmacytoma of bone, plasma cell myeloma, and extraosse

150 Peritoneal plasmacytomas of C.iMyc(Emu) N3 mice overexpressed Myc(H

151 Plasmacytomas of each genotype expressed high levels of

152 lated to immunoblastic lymphomas, less so to plasmacytomas of Fasl mutant and SJL mice, and least to

153 utant and SJL mice, and least to plasmacytic plasmacytomas of IL6 transgenic mice.

154 asmacytomas from NFS.V(+) congenic mice with plasmacytomas of IL6 transgenic, Fasl mutant, and SJL-be

155 onversely, of the 4 pRB(+) HCLs and 3 pRB(+) plasmacytomas, only 1 of each was cyclin D1(+).

156 (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26).

157 tumors arose in peripheral lymphoid organs (plasmacytomas) or within the bone marrow and often led t

158 re-, and mature B-cell lines, but not in two plasmacytomas; Pax-5b was shown to be present at low lev

159 er (10 to 20 microg/mL) profoundly inhibited plasmacytoma (PCT) development initiated by three 0.2- o

160 lammation- and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-assoc

161 Ig deposition and heavy chain diseases, and plasmacytoma (PCT).

162 -activating translocations characteristic of plasmacytomas (PCT), little is known about genetic facto

163 itical oncogenic event in the development of plasmacytomas (PCTs) although it is not sufficient for t

164 Previous work on peritoneal plasmacytomas (PCTs) in mice suggested that PCTs have a

165 Peritoneal plasmacytomas (PCTs) in strain BALB/c (C), the premier e

166 al translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs).

167 ng tumorigenic mutation that occurs in early plasmacytoma precursor cells.

168 Mouse plasmacytomas, previously considered to be homogeneous,

169 ary chromosomal rearrangements contribute to plasmacytoma progression in BALB/c mice.

170 to confirm a suspected diagnosis of solitary plasmacytoma, provided that whole-body MRI is unable to

171 obulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8

172 Solitary plasmacytoma represents a heterogeneous group of patient

173 interactions at an ISRE sequence called the plasmacytoma repressor factor (PRF) element.

174 ally differentiated B cells, is repressed by plasmacytoma repressor factor.

175 mphoid tissues, raising the possibility that plasmacytoma resistance genes may inhibit tumor developm

176 Previously, we have implicated Mtor as a plasmacytoma-resistance locus, Pctr2, in mice.

177 cations in normal and immunized mice of both plasmacytoma resistant and susceptible lineages in the a

178 e BALB/c and C.D2-Idh1-Pep3 mice, but not in plasmacytoma-resistant DBA/2N mice.

179 Plasmacytoma-resistant strains of mice (DBA/2N, C3H/HeJ,

180 bone, plasma cell myeloma, and extraosseous plasmacytoma, respectively.

181 Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myel

182 on to myeloma in patients with solitary bone plasmacytoma (SBP).

183 BM evaluation of patients with solitary bone plasmacytoma (SBP; n = 35) and extramedullary plasmacyto

184 Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) af

185 Solitary extramedullary plasmacytoma (SEP) is a localised proliferation of monoc

186 Mouse plasmacytomas share pathogenetic features in common with

187 most cases of mantle cell lymphoma, HCL, and plasmacytoma show high levels of pRB in contrast to foll

188 All cases of (HCL) and plasmacytoma showed strong pRB staining.

189 by the most prevalent tumors, plasmablastic plasmacytomas, showed them to be most closely related to

190 were multiple myeloma (SIR 1.41) and 38 were plasmacytoma (SIR 7.06).

191 r 1B and Chr 4C7-D2, are suspected to harbor plasmacytoma susceptibility loci; Pctr1 and Pctr2 on Chr

192 ound to be increased approximately 3-fold in plasmacytoma-susceptible BALB/c and C.D2-Idh1-Pep3 mice,

193 s were detected in as many as 73% (32/44) of plasmacytoma-susceptible BALB/cAn mice 30 days after an

194 Treatment of plasmacytoma-susceptible BALB/cAn mice with pristane ind

195 range, 3.1-6.7) and 1 patient with a pleural plasmacytoma (SUVmax, 7.2); the remaining 3 patients had

196 -activating endemic Burkitt lymphoma t(8;14)/plasmacytoma T(12;15) translocation.

197 ess pronounced in patients with bone-related plasmacytomas than in those with hematogenous EMM.

198 558L HI, an interleukin 5-transfected murine plasmacytoma that is infiltrated by numerous degranulati

199 15) found in a subset (approximately 20%) of plasmacytomas that develop "spontaneously" in the gut-as

200 Selecting specific types of mouse plasmacytomas that relate most closely to subtypes of hu

201 However, the kappaB binding complex in the plasmacytomas that were examined lacked c-Rel and instea

202 We have thus examined the ability of murine plasmacytoma to produce disseminated growth similar to t

203 Diffusion chambers injected with X63.Ag-653 plasmacytoma transfectants that constitutively produce r

204 sceptible to inflammation-induced peritoneal plasmacytomas (tumor incidence, 100%; mean tumor onset,

205 ells (IC(50) < 100 nM), inhibits xenografted plasmacytoma tumors in mice, and is synergistically cyto

206 For Burkitt's lymphoma and mouse plasmacytoma tumors, balanced translocation that juxtapo

207 These results suggest that plasmacytomas use a restricted population of B cells tha

208 ntibodies secreted by silicone-induced mouse plasmacytomas using a broader panel of antigens includin

209 Finally, the lncRNA plasmacytoma variant translocation 1 (PVT1) was inhibite

210 TASc-expressed long noncoding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) was triggere

211 ion of miR-1204 through p53 interaction with plasmacytoma variant translocation 1, and miR-1204 induc

212 reported association between variants in the plasmacytoma variant translocation gene (PVT1) and ESRD

213 [95% CI 1.66-3.96]), which is located in the plasmacytoma variant translocation gene PVT1.

214 of the oncogenic long noncoding RNA (lncRNA) Plasmacytoma Variant Translocation-1 (PVT-1), which is a

215 Importantly, in plasmacytomas, VDJ rearrangements that delete most of th

216 Plasmacytomas were CPP32 immunonegative in 4 of 12 (33%)

217 at typically occur in pristane-induced mouse plasmacytomas were detected in secondary lymphoid tissue

218 ch as Burkitt's lymphoma and t(12;15) BALB/c plasmacytomas, where most breakpoints are found near the

219 osphorylated in a subset of IL-6-independent plasmacytomas, whereas other IL-6-independent lines show

220 Subsequently, it was found that plasmacytomas with similar binding chain specificities n

221 n binding properties, but instead, groups of plasmacytomas with specific antigen-binding activities t

222 tro in the absence of IL6 and form abdominal plasmacytomas with visceral involvement when injected in

223 diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 mo

224 silencing of B lymphocyte-specific genes in plasmacytoma x T lymphoma hybrids can be prevented by pr

225 his transcription factor on the phenotype of plasmacytoma x T lymphoma hybrids established a critical

226 wth and prolongs survival in vivo in a human plasmacytoma xenograft model.

227 mechanism of action of PS-341 using a human plasmacytoma xenograft mouse model.

228 ent CD138(+) MM cells and in vivo in a human plasmacytoma xenograft mouse model.